Postdoctoral Researcher: Dr. Bing Cui
Dr. Cui’s primary focus is developing novel immune treatment for patients with Chronic Lymphocytic Leukemia (CLL) that target the protein ROR1, which we found on the surface of leukemic cells, but not on normal non-cancer cells. Because ROR1 is only found on the surface of the leukemia cells, but not on healthy cells, it can serve as an excellent target for therapy. Dr. Cui recently found that vaccination of mice with the adenovirus-containing the ROR1 protein could prevent the mice from dying of leukemia that expressed the ROR1 protein.
“I believe this is one of best labs in the world that integrates basic science research and development of therapies for CLL. I am very thankful to the BCRF for their support of my research.” Dr. Cui
He is also working on the monoclonal antibodies development. Four new anti-ROR1 monoclonal antibodies specific for ROR1 were developed. Dr Cui found that two of these monoclonal antibodies can protect mice from developing leukemia . “With Dr. Kipps’ guidance, I hope we are close to the successful immune therapy of patients with CLL.” In addition, Dr Cui is also exploring the role of ROR1 in other cancers. If ROR1 has a similar role in other tumors, this research could also be beneficial for treatment of other cancers.